Genomic imbalance referring to somatic variation in chromosome copies represents the most frequent event in tumorigenesis. Germline copy number variations (gCNVs) overlapping regions of genomic imbalance harbor similar structural characteristics and thus influence tumor susceptibility. We aimed to test effects of such gCNVs on the risk of lung cancer and chronic obstructive pulmonary disease (COPD). Genomic imbalance of lung cancer was determined by the array comparative genomic hybridization (aCGH), and common gCNVs at these imbalance regions were genotyped in lung cancer-based and COPD-based retrospective studies. Functional assays were conducted to assess function of promising CNVs. A total of 115 genomic imbalances were discovered occurring at a frequency of more than 25%. The CNVR_3425.1, overlapping the chr16q24.1 with genomic imbalance, was significantly associated with increased risks of lung cancer (OR = 1.76; 95% CI = 1.46-2.11) and COPD (OR = 1.98; 95% CI = 1.57-2.51). The increase copy of CNVR_3425.1 forms a new additional truncated FOXF1 adjacent non-coding developmental regulatory RNA (FENDRR) sequences comparing the gene promoter and perturbs the transcriptional factors (TFs) binding to the original FENDRR promoter and further downregulates FENDRR, a long intergenic non-coding RNA (lincRNA) that functions to inhibit lung cancer by affecting expressions of an abundant number of genes, including the tumor suppressor FOXF1. FENDRR can upregulate FOXF1 by competitively binding to miR-424. The TFs early growth response 1 (EGR1) and transcription factor AP-2 alpha (TFAP2A) were further found to involve the CNVR_3425.1-mediated FENDRR dysregulation. These findings suggested the CNVR_3425.1 to be a possibly predictive biomarker for the risk of lung cancer and COPD, and targeted molecular therapy pertaining to FENDRR upregulation may be a valuable pathway to fight two diseases.
Introduction
In recent years, several association studies especially genome-wide association studies have identified a lot of single nucleotide polymorphisms (SNPs) to be idiotypic risk indicators of human diseases. There have been lofty expectations from these SNPs to improve precision prediction of disease risk, but till now appear to have had limited effect. Robert K. Nam et al. reported that a nomogram incorporating several genome-wide association study (GWAS) SNPs and other host factors only had a middling value in the diagnosis of prostate cancer (1) . Qian D.C. et al. also demonstrated that although SNPs contributed a large increase in risk prediction of lung cancer, the value was not high (2) . Such inadequacies were also observed for other diseases (3) (4) (5) . Several reasons have been proposed for this defect, a major of which is 'missing heritability' (6) . 'Missing heritability' refers to those SNPs that cannot account for all of the heritability of diseases on account of other kinds of genetic variant such as copy number variation (CNV) (7, 8) . Since a person's susceptibility to disease depends on a combined effect of all diseaseassociated variants, we still need to put in greater efforts on discovering missing heritability (8) (9) (10) .
Germline copy number variations (gCNV) is one of the major genetic components of missing heritability, which has been recognized as a contributor of cancer risk (11, 12) . Characterized as loss or gain of stretches of DNA, gCNVs have a greater influence on affecting function of covered genes than SNPs, which harbor great contributions to susceptibility of human disease.
Genomic imbalance refers to a genome showing any somatic loss or gain of DNA sequences compared with the reference DNA whole sequence of the genome of interest (13) . It is the most frequent event in tumorigenesis and typically drives cancer with alterations in embedded genes (14) (15) (16) . Relative to genomic imbalance, gCNVs are loss or gain of DNA sequences that may cause effects as similar as genomic imbalance on embedded genes but can be inheritable. Of late, gCNVs have been suggested to be a crucial factor affecting carcinogen-induced genetic imbalance (17, 18) . On account of those genomic imbalances pinpointing various oncogenes and tumor suppressors including coding and RNA genes, we hypothesized that gCNVs overlapping regions with genomic imbalance of lung cancer contribute to the risk of lung cancer. In accordance with this, we performed array comparative genomic hybridization (aCGH) to identify genomic imbalance regions of lung cancer and conducted a two-stage retrospective study with a total of 2072 lung cancer patients and 2077 normal controls to test associations between common gCNVs in genomic imbalance regions and lung cancer risk. We also analyzed effects of promising gCNVs on the risk of chronic obstructive pulmonary disease (COPD) with a total of 1025 COPD patients and 1061 normal lung function controls because COPD is a possible intermediate phenotype of lung cancer. We further carried out a series of experiments to test functions of promising gCNVs.
Materials and methods

Study subjects
All study subjects have been described in previously published studies (19) . In brief, this study totally recruited 1056 lung cancer cases and 1056 healthy controls as well as 1025 COPD patients and 1061 normal lung function controls from Guangzhou region of China and 1016 lung cancer cases and 1021 normal controls as well as 365 COPD cases and 388 normal lung function controls from Suzhou city in China in total. The southern Chinese population was used as a discovery set, and the eastern population was used as a validation set. None of the COPD cases have lung cancer. Detailed information on recruitment of subjects are described in Supplementary Methods, available at Carcinogenesis Online. Meanwhile, 52 pairs of lung cancer tissues and corresponding non-tumor normal tissues were also collected during surgical excision. Each subject had signed a written informed consent. This study was approved by the institutional review boards of Guangzhou Medical University and Soochow University. In addition, the use of mouse was followed along with the institutional review boards of Guangzhou Medical University.
Agilent aCGH analysis
Genomic imbalances were tested in eight randomly selected pairs of lung cancer tissues and adjacent normal tissues using the Agilent SurePrint G3 human CGH 4 × 180K array supplied by a commercial company (Biotechnology Corporation, Shanghai, China).
CNV selection and detection
According to gCNVs information of East Asian population (20) , there are a total of 58 common gCNVs (altered copy number frequency, ACNF > 10%) that are located in described genomic imbalance regions of lung cancer. We further selected eight promising gCNVs, whose chromosome regions bear well-established oncogene or tumor suppressor. Copy numbers of these gCNVs were first detected in randomly selected 110 pairs of cases and age-and sex-matched controls with the Accucopy assay (12) . Then, the promising CNVR_3425.1 was genotyped in all subjects using the Taqman assay. The results were 95.0% concordant between the two assays. Detailed information on genotyping is presented in Supplementary Methods, available at Carcinogenesis Online.
Cell culture
The human lung cancer cell lines A549 and PC-9 were purchased from Cell Bank of Type Culture Collection of the Chinese Academy of Science (Shanghai Institute of Cell Biology, Shanghai, China). Both cell lines were tested and authenticated by the standard short tandem repeat DNA typing methodology before used in this study. All cells were cultured in RPMI1640 medium (Gibco, life technologies, California) supplemented with 10% fetal bovine serum (FBS). Cells were placed in a CO 2 incubator (SANYO Electric Co., Ltd., Japan) with constant 90% humidity and 5% CO 2 .
Gene expression examination
On account of that gCNVs may influence expression of embedded genes (21, 22) , we asked whether expressions of genes residing in CNVR_3425.1 are affected by it. Messenger RNA (mRNA) levels of four coding genes that are forkhead box F1 (FOXF1), methenyltetrahydrofolate synthetase domain containing (MTHFSD), forkhead box C2 (FOXC2) and forkhead box L1 (FOXL1), and two RNA genes that are FOXF1 adjacent non-coding developmental regulatory RNA (FENDRR), FOXC2 antisense RNA 1 (FOXC2-AS1) were examined using the SYBR-Green quantitative real-time PCR (qRT-PCR). Primers for these genes are shown in Supplementary Table S1, available at Carcinogenesis Online.
FENDRR promoter luciferase reporter assay
Given that the CNVR_3425.1 covers a majority of intron 1, exon 1, 5′-untranlated region (5′-UTR) and upstream promoter of FENDRR, we asked whether this new additional truncated FENDRR sequences perturbs FENDRR transcriptional activity. We constructed luciferase reporters carrying single copy or dual copies of the FENDRR promoter via cloning a 1400 bp fragment (from −1400 to 0 bp relative to 
RNA interference and ChIP
We would like to know more about which TFs involving the dysregulation of FENDRR transcription related to the CNVR_3425. 
Construction of the lentivirus vector of FENDRR
The whole cDNA of FENDRR was synthesized and cloned into the lentiviral expression vector pEZ-Lv201 (Genecopoeia Biotech Co. Ltd., Guangzhou, China). The empty pEZ-Lv201 was used as a control. The pEZ-Lv201-FENDRR was further used to construct a lentiviral vector containing truncated version of FENDRR with miR-424 binding site absence by site-directed mutagenesis using the Quick-Change site-directed mutagenesis kit (Stratagene, La Jolla, California). Detailed protocol is presented in Supplementary Methods, available at Carcinogenesis Online.
Cell phenotypic experiments
The lentiviral vector was used for construction of FENDRR stably overexpressed cells and referential cells. The cell counting kit-8 assay and flow cytometry analysis were performed to measure cell proliferation, cell cycle and apoptosis. The Transwell assay with uncoated or Matrigel-coated (BD Biosciences, California) Boyden chambers was conducted to assess cell migration and invasion. The tablet cloning experiment and soft-agar colony assay were applied for inspecting in vitro clonogenesis ability of cells. The nude mouse tumorigenicity assay was employed to measure the in vivo tumorigenesis abilities of cells. The protocols for above assays are described in Supplementary Methods, available at Carcinogenesis Online.
Gene expression profiling analysis
The whole human genome oligo microarray was used to assess alteration of gene expression profiles mediated by FENDRR by a commercial company (Biotechnology Corporation, Shanghai, China).
Bioinformatics analysis on public records of FENDRR
We quested the Cancer Genome Atlas (TCGA) database to validate expressional status of FENDRR in lung cancer and its correlation with cancer survival as well as to explore its related coding genes by constructing FENDRR co-expression network. Available data on FENDRR expression were derived from 979 non-small cell lung cancer (NSCLC) patients in the TCGA data portal (https://portal.gdc.cancer.gov/). The weighted correlation network analysis in R software was used to achieve expression module, and the software Cytoscape was applied for constructing the network diagram.
FOXF1 3′-UTR luciferase reporter assay and microRNA mimics treatment
Since FOXF1 was found to be regulated by FENDRR, we asked what the regulatory mechanism is. Moran N Cabili et.al. have revealed that FENDRR is localized in both nucleus and cytosol (24), implying a possible role of FENDRR as post-transcriptional regulator such as competing endogenous RNA. We thus performed bioinformatics analysis with the starbase v2.0 website to forecast possible FENDRR-FOXF1-miRNA interactions (http://starbase.sysu.edu.cn/mirLncRNA.php) and found that FENDRR and FOXF1 share binding sites of seven microRNAs including miR-15a, miR-15b, miR-16, miR-195, miR-424, miR-496 and miR-708-5p. The 3′-UTR of FOXF1 was cloning into the Psi-CHECK2 luciferase vector. The mimics of above microRNAs were synthesized and used at a concentration of 50 nM in followed luciferase assay. A microRNA mimics with random sequences transfection was used as a control (Mock). Moreover, the FOXF1 expression was further tested in A549 cells after 8 h followed by transfection of 100 nM miR-424 mimics (6 h) and treatment of 2 mg/L actinomycin D (2 h, Sigma, MO). The proliferation of cells in response to miR-424 treatment (100 nM) or FOXF1 siRNA (75 nM) treatment was also assessed.
Statistical analysis
Differences in frequency of copy number between cases and controls were evaluated using the McNemar's χ 2 test. Associations between the CNVR_3425.1 and disease risk were tested by the multivariable logistic regression using the 'PROC logist' with adjustment for age, sex, preexisting TB, pack-year smoked, house ventilation, biomass usage and occupational exposure to metallic toxicant, which were characteristic as risk factors of both diseases in our previous study (25) . Interaction between risk factors and the CNVR_3425.1 was assessed using the multiplicative interaction. The Breslow-Day test was applied for analyzing whether the results were homogenous between stratified ORs. The Logrank test and Cox model with adjustment for age, sex, smoking status histological types and clinical stages were used to evaluate the effect of FENDRR expression on lung cancer survival. Study power was calculated using the PS Software. Differences in numeric data were tested with the Student's t-test or the one-way ANOVA test. Differences in gene expression between cancer tissues and normal ones were assessed by the paired t-test. Correlation between FENDRR and FOXF1 was tested by the Pearson correlation analysis. All tests were two-sided using the SAS software (version 9.3; SAS Institute, Cary, North Carolina). P < 0.05 was considered to be statistically significant.
Results
Characterization of genomic imbalances in lung cancer
The aCGH analysis detected a total of 325 regions with genomic imbalance, ranging from focal rearrangements (70 kb-5 Mb) to chromosome-arm alterations with chromosomal segments amplification or deletion (Figure 1a ). The detailed data has been submitted to the GEO database (GSE89927: https://www. ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89927). Among these mutations, a total of 115 regions occurred at a frequency of more than 25% (Supplementary Table S4 , available at Carcinogenesis Online).
gCNVs in genomic imbalances and lung cancer risk
Eight common gCNVs located in above 115 regions were selected to genotype with regard to well-established tumorrelated genes residing in their regions. They are CNVR_1167.2 at Chr5p15.33, CNVR_1215.1 at Chr13.3, CNVR_1372.1 at Chr5q35.3, CNVR_1994.1 at 8q24.3, CNVR_3339.1 at 16p11.2, CNVR_3367.1 at 16q13, CNVR_3425.1 at 16q24.1 and CNVR_3916.1 at 20q13.13. Figure 1b exhibits one example of region with genomic imbalance at chr16q24.1, and Figure 1c demonstrates chromosome location of the CNVR_3425.1 and its embedded genes. Results from the Accucopy assay showed that the frequency distribution of copy number of CNVR_3425.1 at chr16q24.1 was significantly different between lung cancer cases and matched controls (P = 0.014; Table 1 ). No significant deviation was observed for other gCNVs (P > 0.05 for all; Table 1 ). Genotyping of the CNVR_3425.1 by the Accucopy assay is presented in Figure 1d and those of other ones in Supplementary Figure S1 , available at Carcinogenesis Online.
CNVR_3425.1 increases the risk of lung cancer and COPD
Distributions of demographic variables, selected risk factors and clinical features of all studied samples are shown in Supplementary Table S5 , available at Carcinogenesis Online and have been described elsewhere (19, 26) . We only genotyped the CNVR_3425.1 with promising significance and detected more than three genotypes of copy number using the Taqman assay (Figure 1e ), including common 2-copy genotype and more than 2-copy genotype that were described as ≥3 copy. As shown in Table 2 , compared with the 2-copy carriers, these ≥3-copy ones harbored a significantly increase in risk for developing lung cancer by 70% (OR = 1.70; 95% CI = 1.33-2.18; P = 2.75 × 10 -5 ) in southern Chinese. Data from the eastern Chinese population further confirmed this observation. The ≥3-copy contributed a significantly higher risk to lung cancer than the 2-copy (OR = 1.85; 95% CI = 1.40-2.43; P = 2.75 × 10 -5 ). When merged the two populations, the ≥3-copy predisposed carriers for developing lung cancer when compared with the 2-copy (OR = 1.76; 95% CI = 1.46-2.11; P = 1.86 × 10 -9 ). Moreover, the ≥3-copy consistently increased the risk of COPD by 116, 74 and 98% when compared with the 2-copy in the southern Chinese (OR = 2.09; 95% CI = 1.59-2.76; P = 1.50 × 10 -7 ), eastern Chinese (OR = 1.74; 95% CI = 1.11-2.72; P = 0.015) and merged populations (OR = 1.98; 95%CI = 1.57-2.51; P = 1.28 × 10 -8 ), respectively. In addition, stratification analysis showed no significant difference in the association between CNVR_3425.1 and the risk of lung cancer as well as COPD (Supplementary Table S6 and S7, available at Carcinogenesis Online). Also, no significant interaction was observed between any surrounding factors and the gCNV (Supplementary Table S6 and S7, available at Carcinogenesis Online).
CNVR_3425.1 significantly affects expression of FENDRR but not other embedded genes
The gene expression test showed that the lung cancer tissues carrying the ≥3-copy of CNVR_3425.1 (n = 22) exerted a significantly lower expression of FENDRR than those carrying the 2-copy (n = 30; mean ± standard deviation: 0.028 ± 0.043 versus 0.052 ± 0.037; P = 0.037; Figure 2a) . The ≥3-copy was also Copy number is exhibited as 2-copy/≥3-copy for gain-type CNV, 2-copy/≤1-copy for loss-type CNV, and ≤1-copy/2-copy/≥3-copy for gain/loss-type CNV. *P-value calculated by the McNemar's χ 2 test for matched case-control data. correlated with a decreased expression of FOXF1 in comparison with the 2-copy (0.605 ± 0.591 versus 0.968 ± 0.943). However, the difference was not significant (P = 0.119; Figure 2a) . Furthermore, such an effect was not observed for other genes (P > 0.05 for all; Supplementary Figure S2 , available at Carcinogenesis Online).
CNVR_3425.1 influences the transcriptional efficiency of FENDRR promoter
The construction features of three reporters comprising the different copies of FENDRR promoter are shown in Figure 2b . Only at high concentrations of reporter genes (≥50 ng), the duplicated copies of FENDRR promoter showed significantly weaker luciferase activity when compared with the single copy of FENDRR promoter in both A549 and PC-9 cells, while as expected, the duplicated copies of truncated FENDRR promoter, missing two predicted TFs' binding sites, exerted approaching luciferase activity in comparison with the single copy (Figure 2c) . At low concentrations, no significant difference was observed between the three types of reporter genes.
Knockdown of EGR1 and TFAP2A inhibits activity of the FENDRR promoter
Since almost all siRNAs showed reduced effects on target genes, we selected two siRNAs for each gene according to the degradation effectivity (Supplementary Figure S3a- d, available at Carcinogenesis Online). The luciferase assay further revealed that knockdown of EGR1 or TFAP2A by any one siRNA showed consistently decreased transcriptional activity in comparison with mock transfection (P < 0.05 for all; Figure 2d ). Moreover, following co-transfection of the EGR1/ TFAP2A siRNAs and the pGL3.1-1 copy or pGL3.1-2 copies' reporters into A549 cells, these siRNAs diminished the difference of luciferase activity between the two reporters (Figure 2e ). The ChIP assay further confirmed that both EGR1 and TFAP2A bound to the FENDRR promoter (Figure 2f , Supplementary Figure S3e , available at Carcinogenesis Online), but EGR2 and SP1 did not (Supplementary Figure S3f and g, available at Carcinogenesis Online). 
FENDRR expression was correlated with lung cancer survival
With the TCGA data, we stratified the FENDRR expression by median level of lung cancer tissues. Expressed level equal or greater than median was defined as high, while less than median was defined as low. High expressed FENDRR conferred longer survival time (1790 days versus 1346 days, Log-rank test P = 0.088) and lower fatality rate (hazard ratio = 0.50, 95% CI = 0.25-0.98) when compared with low expressed FENDRR.
FENDRR functions to inhibit tumor growth
FENDRR was downregulated in 76.9% (40/52) cancer tissues when compared with normal tissues (P = 0.025; Figure 3a) . The TCGA data further confirmed that FENDRR expressed a significantly lower level in lung cancer tissues than their normal counterparts in both lung adenocarcinoma (log2(FoldChange) = −3.981, P= 1.98 × 10 ). Additionally, FENDRR was almost undetectable in all lung cancer cell lines. Having established overexpression of FENDRR in transfected A549 and PC-9 cells, we examined effects of FENDRR on phenotypes of lung cancer cells. We found that FENDRR overexpression well reduced the rate of cell proliferation at levels beginning with 1000 cells per well and 500 cells per well in both cells (Figure 3b) . Overexpression of FENDRR led more A549 cells to rest on G0-G1 phase and less PC-9 cells to keep in G2-M phase (P < 0.05 for both; Figure 3c ). However, overexpression of FENDRR exerted no significant effect on cell apoptosis (P > 0.05 for both; Figure 3d ). Furthermore, FENDRR overexpression resulted in sharply declined tumor growth in vitro (P < 0.05 for all; Figure 3e and f). The A549 and PC-9 cells with high expression of FENDRR exhibited significantly decreased growth rate of tumor xenograft compared with their controls in vitro (Figure 4a-c) .
Xu TP et al. have reported that FENDER overexpression suppressed invasion and migration of gastric cancer cells, which are features of tumor progression (27) . However, as shown in Supplementary Figure S4 , available at Carcinogenesis Online, FENDER overexpression did not significantly inhibit both migration and invasion of A549 and PC-9 cells (P > 0.05 for all).
FENDRR drives alteration of cell expression profile
The gene expression profiling analysis identified a total of 559 differentially expressed transcripts (|log2(FoldChange)| > 2) in response to FENDRR overexpression, including 359 downregulated transcripts and 200 upregulated ones (Figure 5a ). The chip data have been submitted to the GEO database (GSE89828: https:// www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89828). 
Gene co-expression network
The weighted correlation network analysis result indicated that FENDRR expression was significantly correlated with expressions of 407 coding genes in lung adenocarcinoma and 40 ones in squamous cell carcinoma, of which 31 genes were common (Figure 5b) . The 31 genes were also mostly revealed by the microarray, including FENDRR neighboring gene FOXF1.
FENDRR upregulates FOXF1 expression via competitively binding to miR-424
The detection of expression showed that FENDRR overexpression upregulated FOXF1 expression (Figure 5c ), and their expressions were positively correlated in lung tissues (r = 0.877, P = 5.56 × 10 -34
; Figure 5d ). FOXF1 was also downregulated in lung cancer tissues when compared with adjacent lung normal tissues with a clear tendency to significance (P = 0.099; Figure 5e ). The luciferase assay further showed that only miR-424 exerted a significant decrease in luciferase activity of FOXF1 3′-UTR in both A549 and PC-9 cells. Such an effect was not observed for other microRNAs (Figure 5f ). The miR-424 mimics caused a significantly less decrease in luciferase activity in A549 cells overexpressed FENDRR (16.9%) than that overexpressed truncated FENDRR (27.7%) and referential cells (33.1%; P < 0.001; Figure 5g ). Moreover, after treatment of the miR-424 mimics, the FOXF1 expression in A549 cells overexpressed FENDRR had a less decrease (21.8%) as compared with referential cells (37.7%) with a considerable trend toward significance (P = 0.058), while that in A549 cells overexpressed truncated FENDRR exerted a similar decrease (35.4%) as compared with referential cells (P = 0.810; Figure 5h ). In addition, following transfection of miR-424 mimics or FOXF1 siRNA, the FOXF1 siRNA induced a significant increase in proliferation rate, whereas miR-424 mimics did not in comparison with control cells as the cell counting kit assay and the tablet cloning experiment shown (Supplementary Figure S5 , available at Carcinogenesis Online).
Discussion
Our knowledge about roles of gCNVs on disease susceptibility and their affinity mechanisms remains limited. Few studies have reported a limited number of gCNVs to be susceptible loci for different cancers, most of which were based on candidate gene strategy and lack of functional evidences. In the current study, we detected the gCNVs in genomic imbalances of lung cancer and identified the CNVR_3425.1 to be a risk indicator of lung cancer and COPD for Chinese populations. We also explicated the mechanism how the gCNV confer susceptibility of both diseases. To the best of our knowledge, this is the first study to investigate on gCNVs in genomic imbalances and a revelation of long intergenic non-coding RNA (lincRNA)-related gCNV.
In this post-GWAS era, gCNV is increasingly drawing attention with respect to their contributions on missing heritability of disease. For lung cancer, several gCNVs that are associated with lung cancer risk have been demonstrated, which highlight the gCNVs as important components of cancer heritability (12, 28, 29) . However, due to the limitations of the candidate gene strategy that focused on gCNVs overlapping well-known cancerrelated coding genes, relationships between most of gCNVs and human disease are unknown and are yet to be elucidated. Under the prevailing condition that cannot implement large-scale gCNV detection, our study chose a low thoroughput technology to test eight promising gCNVs in chromosome regions with genomic imbalance of lung cancer. We identified one gCNV namely CNVR_3425.1 in the region chr16q23.1-24.3 with contribution on increasing the risk of lung cancer and COPD in Chinese populations. Coincidentally, a report based on the SNP genotyping chip reported that the risk gCNVs of lung cancer are located on genomic recombination hotspots (28) . Also, the genetic mutations of chr16q23.1-24.3 have been reported to be implicated in lung developmental disorder and lung cancer (25, 30) . These results highlight the importance of gCNVs in genomic imbalances, and broader studies testing more such gCNVs are warranted.
Several gCNVs have been supposed to affect disease predisposition via their modulatory effects on embedded genes. Here, we proved that the incremental copy of CNVR_3425.1 exerted a decreased expression of FENDRR. Functional mechanisms of gCNV have been documented as gene dosage effect (21,31), distal enhancer regulation (32, 33) and structural mutation induction (34) . Here, due to the negative correlation and superimposed pattern between the gCNV and FENDRR, mapping the increased copy of CNVR_3425.1 and decreased FENDRR is an involved problem. Using the luciferase assay, we have identified that the increased copy of CNVR_3425.1 weakens transcriptional efficiency of FENDRR because the 2-copy luciferase reporter showed reduced transcriptional activity in comparison with the 1-copy one, and the 2-copy truncated one indeed rescued the activity, which exerted under specific condition with high concentrations of reporter gene. After determining the responsible TFs EGR1 and TFAP2A, we further found that knockdown of EGR1 and TFAP2A diminished the difference of luciferase activity between the 1-copy reporter and the 2-copy one. The findings prompt us to speculate that the incremental copy-formed promoter can disturb the TF's binding to the original FENDRR promoter, which depends on low responsible TFs' expression level or great transcriptional demand. When such TFs reduce expression, which might be, for example, induced by carcinogens stimulus, the detrimental function of CNVR_3425.1 is starting to appear. Consistently, downregulation of TFAP2A was observed to promote lung carcinogenesis in response to cigarette smoke condensate (35) . Absent EGR1 was also observed in lung cancer tissues (36) . Furthermore, one previous study has documented a long-range regulation of FENDRR promoter depending on physical interaction as chromatin looping between the region that FENDRR and CNVR_3425.1 overlapped and a putative distant regulatory region (DRR) (37) . The DRR is located in downstream of FENDRR, which exerted an in trans regulation on the FENDRR promoter. These distal transacting factors might have interaction with local factors such as EGR1. Considering the large scale, CNVR_3425.1 would most probably perturb the physically interaction between the DRR and FENDRR promoter, then disrurbing the TF's binding to the FENDRR promoter and ultimately leading to decreased FENDRR. However, to further determine this perturbation of large gCNV-mediated chromatin, interactions seem to be impossible in contemporary condition and need to be solved in the future.
Further analyses supported a tumor suppressor role of FENDRR in lung cancer. FENDRR is a well-established lincRNA (38) , whose absence has been found in lung and gastric tumors, resulting defects in lung and gastrointestinal tract (27, 39, 40 ). Yet, its concrete role on lung tumorigenesis remains an enigma. Here, both in vivo and in vitro experiments showed that FENDRR was downregulated in lung tumor tissues, and high expression of FENDRR was correlated with favorite lung cancer survival. Overexpression of it markedly inhibited cell proliferation and tumor growth. All these demonstrably indicated that FENDRR functions to inhibit lung cancer development. Moreover, we have validated FOXF1 to be a target of FENDRR in lung cancer, which is firstly reported to be a target of FENDRR in pluripotent cells (41) . FOXF1 is located in close proximity to FENDRR and has been identified to be a tumor suppressor (42) . Both our expressional results and TCGA data revealed a significantly positive correlation between FENDRR and FOXF1. Also, knockdown of FOXF1 returned FENDRR-mediated phenotype change. Even it has been known that FENDRR can interact with polycomb repressive complex 2 to facilitate promoter methylation and cause decreased target genes (43) , which cannot explain why FENDRR upregulates FOXF1. One computational study has documented possible mechanism on FENDRR regulation of FOXF1 based on bioinformatics analysis (44) ; yet, the projection lacks experimental evidences. Using the luciferase assay, we have revealed that when presented as a competing endogenous RNA, FENDRR can sponge miR-424, reduce its binding to FOXF1 and then upregulate FOXF1. Consistently, downregulation of miR-424 has been report to act as a cancer suppressor involving lung cancer (45) . However, may be due to highly endogenous expression in A549 cells (46) , the miR-424 mimics did not rescue the FENDRR-mediated decline of cell proliferation. Noticeably, the increased copy of CNVR_3425.1 tends to exert a decreased expression of FOXF1. This is contradictory to the approbable opinion of gene dosage effect, which should have caused upregulated FOXF1, considering copy increase of CNVR_3425.1 duplicates the FOXF1 gene. Therefore, it seems tempting to speculate that the CNVR_3425.1 first damps FENDRR expression and then indirectly results in a net decrease of FOXF1.
In addition, there remains no doubt that FENDRR would cause altered expressions of a series of genes with respect to its epigenetic regulation ability (43) and its effect on FOXF1, which is a probable transcription activator for a number of lung-specific genes (47) . Indeed, our data showed that overexpression of FENDRR results in altered expression of abundant genes. Also, TCGA data further revealed an abundant of coding genes to be associated with FENDRR. These findings further supported FENDRR to be involved in lung cancer and COPD development. Thus, upregulation of FENDRR may be exploited in the treatment of the two diseases.
It is unlikely that the current finding CNVR_3425.1 confers to increased disease risk was achieved by chance, considering that the association was consistent in two studied populations and two contextual diseases and had strong functional experimental evidences. We have also achieved >99.0% study power for both lung cancer and COPD case-control studies. However, being hospital-based case-control studies, bias such as information or selection bias was inevitable. This might cause an error in estimation on association strength between the gCNV and the risk of lung cancer as well as COPD. Moreover, the functional assays only presented an indirect connection between the CNVR_3425.1 and lung cancer phenotypes pass by FENDRR. We have tried to construct a stable A549 cell line with defined number of integrates of the promoter region that are expected to carry 4-copy or 3-copy using the Crispr/cas9 technology, and thus, we can directly observe the genetic effect of the CNVR_3425.1 on FENDRR expression and cell phenotypes. Unfortunately, we always failed to conduct such an experiment due to technical restriction.
Based on case-control studies and a series of functional assays, we have identified the CNVR_3425.1 to be susceptible loci for lung cancer and COPD in Chinese. The ≥3-copy predispose carriers to develop lung cancer and COPD by weakening transcriptional efficiency of the FENDRR promoter and further downregulates FENDRR expression. FENDRR functions to inhibit lung cancer development by affecting expression of an abundant number of genes, including an upregulation of tumor suppressor FOXF1. These data supported the CNVR_3425.1 to be an idiotypic predictor for the risk of lung cancer and COPD in Chinese, and targeted molecular therapy owing to FENDRR upregulation may be valuable pathway to fight two diseases.
